7th Cancer Scientific Forum of the Cancéropôle Lyon Auvergne Rhône-Alpes
暂无分享,去创建一个
B. Coiffier | P. Pauwels | B. Teicher | J. Reichert | C. Klein | C. Dumontet | A. Beck | L. Goetsch | N. Corvaïa
[1] G. Salles,et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. , 2012, Blood.
[2] R. Gascoyne,et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. , 2012, Blood.
[3] Alain Van Dorsselaer,et al. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. , 2012, Analytical chemistry.
[4] Janice M. Reichert,et al. Marketed therapeutic antibodies compendium , 2012, mAbs.
[5] H. Pelicano,et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. , 2012, Blood.
[6] R. Ueda,et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Reichert. Which are the antibodies to watch in 2012? , 2012, mAbs.
[8] Scott C. Williams,et al. Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’ , 2011, The Yale journal of biology and medicine.
[9] C. Klein,et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. , 2011, Blood.
[10] Herren Wu,et al. A glycoengineered anti‐CD19 antibody with potent antibody‐dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo , 2011, British journal of haematology.
[11] M. Sliwkowski,et al. Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer , 2011, Clinical Cancer Research.
[12] A. Younes,et al. Brentuximab Vedotin (SGN-35) , 2011, Clinical Cancer Research.
[13] A. Ricart. Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin , 2011, Clinical Cancer Research.
[14] I. Pastan,et al. Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox , 2011, Clinical Cancer Research.
[15] B. Teicher,et al. Antibody Conjugate Therapeutics: Challenges and Potential , 2011, Clinical Cancer Research.
[16] D. Neri,et al. Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends , 2011, Clinical Cancer Research.
[17] R. Lutz,et al. SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies , 2011, Clinical Cancer Research.
[18] G. Nightingale. Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia , 2011, The Annals of pharmacotherapy.
[19] Janice M Reichert,et al. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies , 2011, mAbs.
[20] M. Czuczman,et al. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. , 2011, Future oncology.
[21] Armin Ruf,et al. Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose , 2011, Proceedings of the National Academy of Sciences.
[22] C. Klein,et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. , 2011, Blood.
[23] B. Teicher,et al. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling. , 2011, International journal of oncology.
[24] H. Kluin-Nelemans,et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] A. Beck,et al. World Antibody Drug Conjugate Summit Europe , 2011, mAbs.
[26] Guy Georges,et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies , 2011, Proceedings of the National Academy of Sciences.
[27] T. Illidge,et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. , 2011, Blood.
[28] R. Elstrom,et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma , 2011, Haematologica.
[29] A. Beck. Biosimilar, biobetter and next generation therapeutic antibodies , 2011, mAbs.
[30] C. Klein,et al. Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells , 2011, British journal of haematology.
[31] Andrew Lister,et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.
[32] M. Hallek,et al. Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies , 2011, Clinical Cancer Research.
[33] J. Reichert. Antibody-based therapeutics to watch in 2011 , 2011, mAbs.
[34] C. Klein,et al. Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101 , 2011, Molecular Cancer Therapeutics.
[35] Janice M Reichert,et al. Metrics for antibody therapeutics development , 2010, mAbs.
[36] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[37] Christian Bailly,et al. The next generation of antibody-drug conjugates comes of age. , 2010, Discovery medicine.
[38] F. d'Amore,et al. Phase II trial of zanolimumab (HuMax‐CD4) in relapsed or refractory non‐cutaneous peripheral T cell lymphoma , 2010, British journal of haematology.
[39] C. Klein,et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.
[40] Christian Bailly,et al. Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.
[41] Teicher Ba. Antibody-drug conjugate targets. , 2009 .
[42] Nancy Whiting,et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] J. Reichert,et al. European Medicines Agency workshop on biosimilar monoclonal antibodies , 2009, mAbs.
[44] P. Tak,et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis , 2009, Annals of the rheumatic diseases.
[45] Andreas Radbruch,et al. B-cell-directed therapies for autoimmune disease , 2009, Nature Reviews Rheumatology.
[46] J. Leonard,et al. A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma , 2009, British journal of haematology.
[47] T. Waldmann,et al. EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies , 2009, Clinical Cancer Research.
[48] J. Rossi,et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.
[49] B. Teicher,et al. Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma , 2008, Clinical Cancer Research.
[50] S. Ansell,et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] T. Illidge,et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. , 2007, Blood.
[52] J. Leonard,et al. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies , 2007, Oncogene.
[53] G. Schwarzer,et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.
[54] P. Parren,et al. The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.
[55] C. Dearden. The role of alemtuzumab in the management of T-cell malignancies. , 2006, Seminars in oncology.
[56] M. Erlanson,et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. , 2004, Blood.
[57] M. Baccarani,et al. Clinical Observations, Interventions, and Therapeutic Trials , 2000 .
[58] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[59] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Camellia W. Adams,et al. An efficient route to human bispecific IgG , 1998, Nature Biotechnology.
[61] R. Lutz,et al. SAR 3419 : An Anti-CD 19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies , 2011 .
[62] B. Teicher. Antibody-drug conjugate targets. , 2009, Current cancer drug targets.
[63] R. Fanin,et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. , 2002, Haematologica.
[64] D. Czerwinski,et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. , 1994, Blood.